Skip to main content

Table 1 Case demographics of post-mortem human cases used in immunohistochemical analyses

From: N-terminally truncated Aβ4-x proteoforms and their relevance for Alzheimer’s pathophysiology

Case

PMI (h)

AAO (years)

AAD (years)

Duration (years)

Gender

Diagnosis

Brain weight (g)

APOE

Braak Tau

Thal phase

CERAD

ABC

CAA

1

115:35

49

54

5

M

AD

910

2/3

6

5

3

A3B3C3

3

2

33:26

63

74

11

M

AD

1022

4/4

6

5

3

A3B3C3

3

3

75:20

59

75

16

F

AD

1057

3/4

6

5

3

A3B3C3

3

4

58:50

43

58

15

F

AD

1075

3/3

6

5

2

A3B3C2

3

5

85:35

72

88

16

M

AD

1120

3/4

6

5

3

A3B3C3

1

6

58:10

72

88

16

M

AD

1084

2/3

6

5

2

A3B3C2

3

7

134:20

70

79

9

M

AD

1425

3/4

6

5

3

A3B3C3

3

8

60:00

62

76

14

F

AD

1020

3/4

6

5

3

A3B3C3

3

9

50:35

79

88

9

F

AD

944

3/4

6

5

3

A3B3C3

3

10

90:20

70

86

16

F

AD

1065

3/4

6

5

3

A3B3C3

3

11

40:10

na

77

na

M

Control

1327

2/2

0

0

0

A0B0C0

2

12

29:30

na

78

na

F

Control

1225

2/2

2

0

0

A0B2C0

0

13

38:50

na

71

na

M

Control

1480

3/3

1

0

0

A0B1C0

0

  1. Cases were pathologically diagnosed with AD based on the current diagnostic criteria. Control cases were selected based on the absence of any neurological disorder.
  2. PMI post-mortem interval recorded in hours; AAO age at disease onset; AAD age at death; CAA cerebral amyloid angiopathy; F female; M male